Bill Sibold
-
Madrigal’s Rezdiffra Nears Blockbuster Status With $958M in First Full Year on Market
In its first full year on the market, West Conshohocken-based Madrigal Pharmaceuticals’ flagship drug Rezdiffra nearly got to blockbuster status, bringing in $958.4 million in…
-
Madrigal Pharmaceuticals First to Receive FDA Clearance for a NASH Treatment
Madrigal Pharmaceuticals has been given Food and Drug Administration market clearance for its experimental treatment for NASH, a fatty liver disease that causes inflammation of…
Founding Partners
Advertisement
Affiliate Partners
